Lenalidomid Hexal

Lenalidomide, the active ingredient in Lenalidomid Hexal, is an immunomodulatory drug presented as an oral tablet for oral use. It is indicated for the treatment of certain hematologic malignancies, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma, in adult patients.

GNH USA supplies Lenalidomid Hexal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Lenalidomid Hexal is an immunomodulatory agent used in the management of specific blood cancers.

- Multiple myeloma: improves progression‑free survival and overall response when combined with dexamethasone and other agents. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and can induce cytogenetic remission. - Mantle cell lymphoma: contributes to disease control as part of combination therapy in relapsed or refractory cases.

Lenalidomid Hexal may cause a range of adverse reactions.

Common Side Effects: - Fatigue - Neutropenia - Thrombocytopenia - Diarrhea - Rash - Constipation

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia or infection - Secondary primary malignancies - Hepatic toxicity - Tumor lysis syndrome - Severe cutaneous reactions such as Stevens‑Johnson syndrome

Before initiating therapy, clinicians should consider several safety measures.

- Pregnancy: contraindicated; teratogenic (Category X). - Thromboembolic risk: assess and consider prophylaxis in patients with additional risk factors. - Hematologic monitoring: perform regular CBC to detect neutropenia or thrombocytopenia. - Renal impairment: adjust dosing and monitor renal function. - Drug interactions: avoid concomitant use with strong CYP inducers without supervision. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Lenalidomid Hexal can interact with several medication classes.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: immunosuppression may diminish vaccine efficacy.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase drug exposure. - P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma concentrations. - Other immunomodulatory agents (e.g., thalidomide): additive hematologic toxicity.